The impact of activated protein C resistance on the patency of arteriovenous grafts for hemodialysis access

2021 ◽  
Author(s):  
Stefanie Christine Santler ◽  
Peter Konstantiniuk ◽  
Georg Schramayer ◽  
Florian Prüller ◽  
Gregor Siegl ◽  
...  
1998 ◽  
Vol 80 (08) ◽  
pp. 344-345 ◽  
Author(s):  
Pasra Arnutti ◽  
Motofumi Hiyoshi ◽  
Wichai Prayoonwiwat ◽  
Oytip Nathalang ◽  
Chamaiporn Suwanasophon ◽  
...  

1995 ◽  
Vol 74 (03) ◽  
pp. 993-994 ◽  
Author(s):  
Johannes Sidelmann ◽  
Jørgen Gram ◽  
Ole Dyg Pedersen ◽  
Jørgen Jespersen

1997 ◽  
Vol 130 (2) ◽  
pp. 202-208 ◽  
Author(s):  
Justo Aznar ◽  
Piedad Villa ◽  
Francisco España ◽  
Amparo Estellés ◽  
Salvador Grancha ◽  
...  

2001 ◽  
Vol 16 (11) ◽  
pp. 862-863
Author(s):  
Sinan Mahir Kayiran ◽  
Namik Özbek ◽  
Kürsat Tokel ◽  
Sükrü Mercan ◽  
Fusun Alehan

1996 ◽  
Vol 1 (4) ◽  
pp. 275-280 ◽  
Author(s):  
Howard Daniel Hoerl ◽  
Aldo Tabares ◽  
Kandice Kottke-Marchant

Activated protein C resistance (APCR) is a recently discovered, medically important cause of venous thrombosis. More than 95% of cases are due to factor V Leiden (FVL), a mutated form of factor V that is resistant to degradation by activated protein C. The prevalence of this disorder, which is inherited in an autosomal dominant fashion, is approximately 5% among asymptomatic people of European heritage. In addition, 20 to 60% of patient cohorts with previous thrombosis demonstrate APCR, making it the most common known genetic cause of abnormal thrombophilia. Current laboratory techniques available for diagnosis include functional assays, such as the APC ratio, as well as DNA-based tests that detect the specific genetic anomaly responsible for FVL. A case report is presented, along with a review of the literature highlighting epidemiology, pathogenesis, clinical features and methods for laboratory diagnosis.


Sign in / Sign up

Export Citation Format

Share Document